SENTANTE: Fully Robotic Peripheral Endovascular Interventions
NCT ID: NCT06537947
Last Updated: 2025-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2024-07-19
2024-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will be a single-center, prospective investigation, designed to evaluate the safety, feasibility, and initial efficacy of robotic system for remote endovascular interventions in adults with disease which requires peripheral endovascular treatment with compatible devices. Participants meeting the inclusion criteria will undergo endovascular interventions using SENTANTE robotic system. Data will be collected through clinical assessments, imaging and other studies, laboratory tests, and feedback from medical personnel and patients.
The study will adhere to ethical guidelines, obtain informed consent from all participants, and be conducted under the oversight of the Clinical Events Committee.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cerebral Protection in Transcatheter Aortic Valve Replacement
NCT02214277
Prospective Study of the SoundBite™ Crossing System in Complex Peripheral CTOs
NCT03933657
CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)
NCT01076036
The Complete® Self-Expanding Stent and Stent Delivery System Registry
NCT00730730
Sentinel Low Risk Registry
NCT04131127
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endovascular interventions
Endovascular intervention using the SENTANTE endovascular robotic system
1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.
2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.
3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endovascular intervention using the SENTANTE endovascular robotic system
1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.
2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.
3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is willing and able to provide appropriate study-specific informed consent and follow Clinical Investigation Plan (CIP) procedures.
* Life expectancy ≥ 12 months from the date of the index procedure.
* Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
* Subject is diagnosed with a disease which requires peripheral endovascular intervention using compatible with SENTANTE guidewires and catheter-based devices.
Exclusion Criteria
* Subjects with myocardial infarct or cerebrovascular event within 3 months prior to index procedure.
* Severe vascular anatomy that would preclude safe sheath insertion, or deliverability of stent.
* History of bleeding diathesis or coagulopathy.
* History of thrombophilia.
* Sensitivity to contrast media that cannot be adequately pre-treated.
* Sensitivity to both forms of CIP-acceptable anticoagulation strategies (i.e., both heparin AND Bivalirudin).
* Sensitivity to an antiplatelet agent AND all CIP acceptable alternative antiplatelet options.
* Major neurologic deficit with NIHSS of ≥ 15.
* Clinical condition that, in the opinion of the investigator, makes endovascular therapy impossible or hazardous.
* Subject previously enrolled in this clinical trial.
* Possible / probable non-compliance of subject with CIP required follow up or medication.
* Subject is currently participating in another clinical trial that has not completed its primary endpoint assessment or would confound this Clinical Study.
* Signs of SARS-CoV2 (COVID-19) active infection.
* Patients with intervention-related anxiety, separation anxiety, autophobia and individuals that cannot be left alone without additional sedation or close supervision.
19 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KCRI
OTHER
SIA Kotello
UNKNOWN
Syntropic Corelab
UNKNOWN
Inovatyvi Medicina UAB
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dainis Krievins, Prof PhD MD
Role: PRINCIPAL_INVESTIGATOR
Pauls Stradins Clinical University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pauls Stradins Clinical university hospital
Riga, , Latvia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIV-24-05-047118
Identifier Type: OTHER
Identifier Source: secondary_id
24-SEN-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.